Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080223792
JPRN-jRCT2080223792CompletedPhase 3

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Takeda Pharmaceutical Company Limited0 sites454 target enrollmentStarted: January 31, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
454
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 18age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •1. Has morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) (i.e., with white blood cell [WBC] <13,000/microliter [mcL])) or low-blast acute myelogenous leukemia (AML).
  • •2. Has MDS or CMML and must also have one of the following Prognostic Risk Categories, based on the Revised International Prognostic Scoring System (IPSS-R):
  • •- Very high (>6 points).
  • •- High (>4.5-6 points).
  • •- Intermediate (>3-4.5 points): a patient determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of >=5% bone marrow myeloblasts.
  • •3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  • •4. Participants with AML (20%-30% blasts) must have a treatment-related mortality (TRM) score >=4 for intensive, induction chemotherapy as calculated using the simplified model described by Walter and coworkers.
  • •Calculation of TRM score:
  • •- 0 for (age <61 years), +2 for (age 61-70 years), +4 for (age >=71 years).
  • •- + 0 for (PS=0), +2 for (PS=1), +4 for (PS >1).
  • •- + 0 for (platelets <50), +1 for (platelets >=50).

Exclusion Criteria

  • •1. HR MDS or low-blast AML with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.
  • •2. Has acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
  • •3. Participants with AML with a WBC count >50,000/ mcL. Participants who are cytoreduced with leukapheresis or with hydroxyurea may be enrolled if they meet the eligibility criteria.
  • •4. Is eligible for intensive chemotherapy and/or allogeneic stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:
  • •- Age >75.
  • •- Comorbidities.
  • •- Inability to tolerate intensive chemotherapy (e.g., participants with AML with 20%-30% blasts and TRM >=4).
  • •- Physician decision (e.g., lack of available stem cell donor).
  • •- The reason a participant is not eligible should be documented in the electronic case report form (eCRF).
  • •5. Has either clinical evidence of or history of central nervous system involvement by AML.
  • •6. Has active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
  • •7. Is diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease.
  • •8. Has nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
  • •9. Has prothrombin time (PT) or aPTT >1.5 x upper limit of normal (ULN) or active uncontrolled coagulopathy or bleeding disorder. Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.
  • •10. Has known human immunodeficiency virus (HIV) seropositive.
  • •11. Has known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection. Note: Participants who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load.
  • •12. Has known hepatic cirrhosis or severe preexisting hepatic impairment.
  • •13. Has known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), and/or myocardial infarction within 6 months before first dose, or severe pulmonary hypertension.
  • •14. Has treatment with strong cytochrome P 3A (CYP3A) inducers within 14 days before the first dose of pevonedistat.

Investigators

Similar Trials

Active, not recruiting
Not Applicable
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refacroty amyloidosis.Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisMedDRA version: 15.0Level: PTClassification code 10024459Term: Light chain diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-005468-10-ITMILLENNIUM PHARMACEUTICALS, INC.248
Active, not recruiting
Phase 1
A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinavir (LPV)/Ritonavir (RTV)/1400mg/533mg/133mg Twice Daily (BID) and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological FailureTreatment of heavily pretreated patients
EUCTR2004-003827-10-ESGlaxoSmithKline, S.A.
Active, not recruiting
Phase 1
A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinavir (LPV)/Ritonavir (RTV)/1400mg/533mg/133mg Twice Daily (BID) and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological FailureTreatment of heavily pretreated patients
EUCTR2004-003827-10-GBGlaxoSmithKline R&D
Active, not recruiting
Not Applicable
A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinavir (LPV)/Ritonavir (RTV) 1400mg/533mg/133mg Twice Daily (BID) and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure.
EUCTR2004-003827-10-ITGLAXO SMITHKLINE
Active, not recruiting
Not Applicable
A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinavir (LPV)/Ritonavir (RTV)/1400mg/533mg/133mg Twice Daily (BID) and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure
EUCTR2004-003827-10-DEGlaxoSmithKline R&D150